Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
EHA
Filter by Topic
2018 EHA Congress Highlights
EHA 2014
EHA 2016
EHA 2016 – Leukemia
Venetoclax Is Safe and Effective When Combined with Rituximab in Relapsed CLL
EHA 2016
,
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
Read Article
Understanding the Subsets of Lymphoma and Treating for Them
By
Joseph Connors, MD
EHA 2016
,
EHA
Videos
Joseph Connors, MD, explains how the understanding of the disease has evolved leading to the categorization of subsets and consequently resulted in the development of newer therapies to address these subsets.
Read Article
Tailoring Treatment
By
Nikhil Munshi
EHA
,
EHA 2016
Videos
Nikhil Munshi talks about modifying treatment to patients' expectations and what they can tolerate.
Read Article
Stopping TKIs Safe after Deep Molecular Response
By
Robert Osborne
EHA 2014
,
EHA
August 2014, Vol 5, No 6
Milan, Italy—More than 60% of patients with chronic myeloid leukemia (CML) were free of relapse 6 months after stopping tyrosine kinase inhibitor (TKI) therapy that led to deep molecular remission, according to the interim results from an ongoing trial reported by Susanne Saussele, MD, of Universitätsmedizin Mannheim, Germany, at the 2014 European Hematology Association meeting.
Read Article
Older Patients with AML Live Longer with Azacitidine
By
Robert Osborne
EHA 2014
,
EHA
August 2014, Vol 5, No 6
Milan, Italy—Older patients with acute myeloid leukemia (AML) gained a “clinically significant,” if not statistically significant improvement in survival when treated with azacitidine (Vidaza) rather than with conventional therapy, reported Hervé Dombret, MD, hematologist, Hôpital Saint Louis in Paris, France, at the European Hematology Association meeting.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma